NeuroVirt key facts
as of Oct 2026- Developer of an XR rehabilitation platform designed to support engaging therapy, precise compensation control, and accurate remote monitoring for improved clinical care.
- NeuroVirt is valued at approximately $11.0M as of Oct 2026 (last reported valuation).
- It has raised $2.1M; the latest was Grant ($700K) in Oct 2025.
- Notable investors include Innovate UK, Endless Frontier Labs, Texas Medical Center, Genesis Ventures (Greece), LifeArc — 14 tracked in total.
- Status: Privately Held (backing).
NeuroVirt's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch NeuroVirt: the Monday email on marks, rounds and moves
NeuroVirt funding rounds
No funding rounds for NeuroVirt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs NeuroVirt
14+NeuroVirt valuation
NeuroVirt's last reported valuation was $11 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
NeuroVirt investors
14 investors are on record for NeuroVirt, including Innovate UK, Endless Frontier Labs, Texas Medical Center and Genesis Ventures (Greece).
About NeuroVirt
Developer of an XR rehabilitation platform designed to support engaging therapy, precise compensation control, and accurate remote monitoring for improved clinical care. The company offers therapy tools, real-time motion tracking, and clinician-controlled compensation settings, enabling physical and occupational therapy providers to deliver personalized, data-driven rehabilitation.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 10
- Website
- neurovirt.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.